Andrea Cavazzoni

List of Publications by Year
in descending order

70 papers	2,347 citations	126907 33 h-index	223800 46 g-index
71 all docs	71 docs citations	71 times ranked	3830 citing authors

#	Article	IF	Citations
1	YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs. JTO Clinical and Research Reports, 2022, 3, 100278.	1.1	3
2	It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer. Life, 2022, 12, 960.	2.4	1
3	Abstract 3011: Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models. , 2021, , .		0
4	Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Life, 2021, 11, 843.	2.4	5
5	Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib. Cancers, 2021, 13, 6.	3.7	30
6	Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines. Frontiers in Oncology, 2020, 10, 563249.	2.8	18
7	Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 5165.	4.1	21
8	New Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma. Anticancer Research, 2020, 40, 4913-4919.	1.1	9
9	Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 666.	3.7	24
10	Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies. , 2019, , 25-60.		2
11	Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion. Targeted Oncology, 2019, 14, 619-626.	3.6	33
12	PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition. Cancers, 2019, 11, 1318.	3.7	61
13	Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells. Scientific Reports, 2019, 9, 13014.	3.3	62
14	Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. Journal of Experimental and Clinical Cancer Research, 2019, 38, 222.	8.6	45
15	Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR. European Journal of Medicinal Chemistry, 2019, 162, 507-524.	5.5	11
16	MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report. Translational Oncology, 2019, 12, 116-121.	3.7	37
17	The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. Journal of Experimental and Clinical Cancer Research, 2018, 37, 72.	8.6	68
18	Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma. Journal of Thoracic Disease, 2018, 10, S194-S206.	1.4	12

#	Article	IF	Citations
19	Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model. Journal of Thoracic Disease, 2018, 10, S207-S220.	1.4	11
20	Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands. European Journal of Medicinal Chemistry, 2017, 128, 140-153.	5.5	58
21	Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. Tumor Biology, 2017, 39, 101042831769502.	1.8	73
22	Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. Neoplasia, 2017, 19, 637-648.	5.3	81
23	New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway. Frontiers in Oncology, 2017, 7, 170.	2.8	21
24	Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. Journal of Experimental and Clinical Cancer Research, 2017, 36, 174.	8.6	70
25	Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. Oncotarget, 2017, 8, 53068-53083.	1.8	19
26	Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. Oncotarget, 2017, 8, 91841-91859.	1.8	28
27	Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation. Journal of Thoracic Oncology, 2016, 11, 1051-1063.	1.1	58
28	Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines. PLoS ONE, 2015, 10, e0141795.	2.5	51
29	Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method. PLoS ONE, 2015, 10, e0142891.	2.5	11
30	Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. Molecular Cancer Therapeutics, 2015, 14, 1916-1927.	4.1	43
31	FGFR as potential target in the treatment of squamous non small cell lung cancer. Cancer Treatment Reviews, 2015, 41, 527-539.	7.7	55
32	404 Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung. European Journal of Cancer, 2014, 50, 129.	2.8	0
33	Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. Cancer Chemotherapy and Pharmacology, 2014, 73, 299-307.	2.3	27
34	692: Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations. European Journal of Cancer, 2014, 50, S166-S167.	2.8	0
35	Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. Molecular Cancer, 2014, 13, 143.	19.2	55
36	Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5290-5294.	2.2	3

#	Article	IF	Citations
37	Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPKâ€“mTORC1 signaling. Breast Cancer Research and Treatment, 2013, 141, 67-78.	2.5	65
38	Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Nonâ€“Small Cell Lung Cancer. Neoplasia, 2013, 15, 61-IN18.	5.3	13
39	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. Current Pharmaceutical Design, 2013, 19, 818-832.	1.9	24
40	Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification. PLoS ONE, 2013, 8, e78656.	2.5	39
41	Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Current Pharmaceutical Design, 2013, 19, 818-32.	1.9	12
42	347 Evaluation of Gefitinib Maintenance in an EGFR-mutant NSCL Cell Line With Acquired Resistance. European Journal of Cancer, 2012, 48, S84-S85.	2.8	1
43	1019 Erlotinib Potentiates Cetuximab-dependent Cell Citotoxicity in Egfr Wild Type Nsclc Cell Lines. European Journal of Cancer, 2012, 48, S246.	2.8	0
44	Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Letters, 2012, 323, 77-87.	7.2	78
45	Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines. Molecular Cancer, 2012, 11, 91.	19.2	35
46	Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. Journal of Medicinal Chemistry, 2012, 55, 2251-2264.	6.4	53
47	Isolation of circulating lung tumour cells using a non-EpCAM-based capture method. Rivista Italiana Della Medicina Di Laboratorio, 2012, 8, 116-117.	0.4	1
48	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. Current Pharmaceutical Design, 2012, 19, 818-832.	1.9	1
49	Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines. Molecular Cancer, 2011, 10, 143.	19.2	36
50	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents. Bioorganic and Medicinal Chemistry, 2011, 19, 2541-2548.	3.0	54
51	Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion. Mini-Reviews in Medicinal Chemistry, 2011, 11, 1019-1030.	2.4	37
52	Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Research and Treatment, 2010, 124, 79-88.	2.5	35
53	Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines. Biochemical Pharmacology, 2010, 80, 179-187.	4.4	31
54	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents. Bioorganic and Medicinal Chemistry, 2010, 18, 5873-5884.	3.0	67

#	Article	IF	Citations
55	Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary studyâ˜†. European Journal of Cardio-thoracic Surgery, 2010, 37, 557-565.	1.4	28
56	Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion. Journal of Medicinal Chemistry, 2010, 53, 2038-2050.	6.4	49
57	Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochemical Pharmacology, 2009, 78, 460-468.	4.4	71
58	TRAILâ€induced apoptosis of FHITâ€negative lung cancer cells is inhibited by FHIT reâ€expression. Journal of Cellular Physiology, 2009, 220, 492-498.	4.1	3
59	5-Benzylidene-hydantoins: Synthesis and antiproliferative activity on A549 lung cancer cell line. European Journal of Medicinal Chemistry, 2009, 44, 3471-3479.	5.5	38
60	Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Molecular Cancer Therapeutics, 2008, 7, 361-370.	4.1	63
61	Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 1104-1111.	1.1	32
62	Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line. Cancer Letters, 2007, 246, 69-81.	7.2	17
63	Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress. Journal of Physiology, 2006, 576, 391-401.	2.9	57
64	5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4021-4025.	2.2	75
65	Hypertonic Stress and Amino Acid Deprivation Both Increase Expression of mRNA for Amino Acid Transport System A. Journal of General Physiology, 2005, 125, 37-39.	1.9	10
66	Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line. Oncogene, 2004, 23, 8439-8446.	5.9	36
67	Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells. Journal of Physiology, 2004, 555, 757-767.	2.9	20
68	Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis. Journal of Physiology, 2002, 540, 499-508.	2.9	79
69	Osmotic Regulation of ATA2 mRNA Expression and Amino Acid Transport System A Activity. Biochemical and Biophysical Research Communications, 2001, 283, 174-178.	2.1	49
70	Induction of BGT-1 and amino acid System A transport activities in endothelial cells exposed to hyperosmolarity. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 279, R1580-R1589.	1.8	32